Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
When the FDA’s Janet Woodcock pushed through a controversial approval for Sarepta’s Exondys 51 for Duchenne muscular dystrophy in September, she created a test case for payers who were essentially being asked to reimburse for an experimental drug.
But instead of rolling with the situation and paying a price that starts at $300,000 or so a year, many of the payers are kicking back hard, according to a survey of payers conducted by Jefferies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
